邮箱：lutiangong@163.com
个人简介
卢天公，特聘教授，博士生导师，北京中医药大学青年优秀人才。北京中医药大学中药学（生物制药方向）学士，英国诺丁汉大学药物化学博士，美国密歇根大学药物化学博士后。担任中华中医药学会血液病分会委员、中国园艺学会药用植物分会常务委员等社会职务。 入选国家中医药管理局中医药国际交流人才库。
研究方向
中西医结合抗肿瘤药物研究、中医药防治消化道癌前病变
主要成果
主持国家自然科学基金青年项目、面上项目及其他省部级科研项目共6项；获国家发明专利1项；以第一作者或通讯作者在国内外学术期刊发表论文10余篇，累计影响因子超过70。多次受邀在国际高水平学术会议上作主旨报告。通讯或一作代表性论文：
(1) Mengwei Xue, Zixuan Bu, Kaile Ke, Jiawei Tian, Xingzheng Zheng, Nouri Neamati, Jianhui Ma, Haiyun Yu, Wei Li, Qing Dong, Fangfang Chen, Tiangong Lu; Guizhi-Fuling Wan suppresses carcinoma-associated mesenchymal stem cells-induced ovarian cancer progression via STAT3 inhibition, Phytomedicine, 2025, 148, 157475, IF=8.3, 中科院一区。
(2) Tiangong Lu , Fangfang Chen, J. Yao, Zixuan Bu, A. Kyani, B. Liang, S. Chen, Y. Zheng, H. Liang, Nour Neamati, Yanghan Liu; Design of FK866-Based Degraders for Blocking the Nonenzymatic Functions of Nicotinamide Phosphoribosyltransferase. Journal of Medicinal Chemistry, 2024, 67, 8099-8121, IF=6.8, 中科院一区。
(3) Qihong Ma; Fangfang Chen; Ying Liu; Kang Wu; Zixuan Bu; Chentao Qiu; Nouri Neamati; Tiangong Lu; Integrated transcriptomic and proteomic analysis reveals Guizhi-Fuling Wan inhibiting STAT3-EMT in ovarian cancer progression, Biomedicine & Pharmacotherapy, 2024, 170, IF=7.5, 中科院二区。
(4) Tiangong Lu; Jianming Tang; Binita Shrestha; Blake R. Heath; Li Hong; Yu L. Lei; Mats Ljungman; Nouri Neamati; Up-regulation of hypoxia-inducible factor antisense as a novel approach to treat ovarian cancer, Theranostics, 2020, 10(15): 6959-6976, IF=13.3, 中科院一区。
(5) Tiangong Lu; Armand Bankhead; Mats Ljungman; Nouri Neamati; Multi-omics profiling reveals key signaling pathways in ovarian cancer controlled by STAT3, Theranostics, 2019, 9(19): 5478-5496, IF=13.3, 中科院一区。